<DOC>
	<DOC>NCT02672306</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety and the efficacy of (Human Umbilical Cord-Derived Mesenchymal Stem Cells) UCMSCs for patients with Alzheimer's disease (AD).</brief_summary>
	<brief_title>Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease</brief_title>
	<detailed_description>Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Randomized, Safety/ Efficacy Study Official Title: Multicenter, Randomized, Double-blind, Placebo Controlled Trial of UCMSCs in Subjects With Alzheimer's Disease</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>A diagnosis of probable AD and Mixed Dementia according to the criteria of the NINCDSADRDA History of cognitive decline that had been gradual in onset and progressive over at least 6 months MMSE score between 3 and 20, both inclusive Home monitoring available for supervision of medications Voluntarily participating subject who sign the Inform Concent Subject with positive test for Human Immunodeficiency Virus(HIV) Subject who cannot undergo Magnetic Resonance Imaging(MRI), computed tomography(CT) screening Subject with psychological diseases (i.e. depression, schizophrenia, bipolar disorder, etc) Subject with cancer Subject with dementia caused by other than Alzheimer's disease (i.e. infection of central nervous system, CreutzfeldtsJacob disease, severe head trauma, Pick's disease, Huntington's disease, and Parkinson's disease) Subject with severe white matter hyperintensities (WMH); Severe WMH is defined that length of the deep white matter is 25 mm or longer and length of the periventricular capping/banding is 10 mm or longer Subject who have had stroke in 3 months Subject with severe kidney failure (1.5 mg/dL of serum creatinine or more) Hemoglobin &lt; 9.5 g/dL for men, &lt; 9.0 g/dL for women; Total white blood count &lt; 3000/mm3; Total bilirubin ≥ 3 mg/dL Active hepatic or renal disease Subject who have been excluded in the subject selection process for this study before Subject who is determined inappropriate by the investigators Subject who is allergic constitution History of screening failure for the clinical trial of neural stem cells A platelet count &lt; 150,000/mm3; Plasma prothrombin time(PT)≥ 1.5; the international normalized ratio (INR) or activated partial thromboplastin time(aPTT)≥ 1.5 x control value Participation in another clinical trial within the three months prior to the beginning (Week 0) of this clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>